Pharma shows limited progress in fight against drug-resistant infections, report finds

The article captures the key takeaways from the report, namely, the shrinking antimicrobial pipeline and lack of investment in AMR by large, pharmaceutical companies, but also highlights bright spots from the findings.

It mentions two promising projects – by Innoviva and GSK – that target resistant pathogens, which demonstrate current industry progress.

It also highlights five companies – Aurobindo, GSK, Hikma, Sandoz and Teva – which register child-friendly antibiotic formulations in countries where they market their other antimicrobial products. This was included in the report to highlight good behaviour and set an example for peer companies to take similar action.

The article quotes Jayasree K. Iyer, CEO of the Access to Medicine Foundation: “We can tilt the battle against superbugs in humanity’s favour. Our findings show practical approaches that can ramp up progress on all fronts.